knowcompoundsazithromycin
Specimen compound organic compoundPlate I
Azithromycin

- Formula
- C38H72N2O12
- Molar mass
- 748.996 g/mol
- ChEBI
- CHEBI:2955
- InChIKey
- MQTOSJVFKKJCRP-BICOPXKESA-N
– no difference found
01 · the evidence, ordered
What the evidence says
- Very limited
Azithromycin
36 compounds on the outer ring, not drawn
Keys
← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it
02 · findings
What azithromycin moved, and by how much
- MD mean difference · OR odds ratio. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
- Duration of mechanical ventilationMoved: no difference foundEffect, as reportedMD0.13[−1.35 to 1.6]Evidence: Very limitedPaper: PMID 407958092026
- Who
- preterm infants (meta-analysis of 6 RCTs, 1,360 infants; azithromycin vs placebo, whole population not restricted by Ureaplasma status)
- Dose studied
- not reported
The composite of BPD or death (RR: 0.95; 95% CI: 0.83-1.10; p = 0.53; I2 = 50.2%), BPD (RR: 0.98; 95% CI: 0.83-1.15; p = 0.77; I2 = 38.1%), death (RR: 0.88; 95% CI: 0.66-1.19; p = 0.41; I2 = 0%), NEC (RR: 0.94; 95% CI: 0.69-1.26; p = 0.67; I2 = 0%), IVH (RR: 1.22; 95% CI: 0.89-1.68; p = 0.22; I2 = 3.5%), RoP (RR: 1.35; 95% CI: 0.43-4.28; p = 0.61; I2 = 76.3%), duration of mechanical ventilation (MD: 0.13; 95% CI: -1.35 to 1.60; p = 0.87; I2 = 0%), and postnatal corticosteroid requirement (RR: 0.84; 95% CI: 0.64-1.08; p = 0.18; I2 = 34.5%) were similar between the groups.”
Quoted verbatim from Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis.meta-analysisPermalink - All-cause mortalityMoved: no difference foundEffect, as reportedOR0.96[0.88 to 1.05]Evidence: Very limitedPaper: PMID 340776002022
- Who
- Patients with Covid-19; seven randomized trials, 8822 patients in total, azithromycin versus standard of care
- Dose studied
- not reported
The use of AZM was not associated with mortality in Covid-19 patients (OR = 0.96, 95% CI 0.88-1.05, p = 0.317 based on the random-effect meta-analysis).”
Quoted verbatim from Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.meta-analysisPermalink
No row matches these filters.
No dose is advised.
- MD mean difference · OR odds ratio. Brackets: the interval as reported.
- Dose studied: as its paper gave it.
- Evidence strength: computed from the study. How it is computed
03 · identity
Structure
- Charge
- 0
- SMILES
- CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
04 · the record
Sources
1,268
papers screened for azithromycin
- admitted
- 3
- read and discarded
- 100
- not read yet
- 1,165
- Documented interactions
- None reported
Sources cited
2 papers · 2 findings
1 admitted at screening, no finding yet